BiondVax Pharma (BVXV) Reports Q2 Loss of NIS0.05/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BiondVax Announces Second Quarter 2015 Financial Results and Update
August 24, 2015 1:30 AM EDTNES ZIONA, Israel, Aug. 24, 2015 /PRNewswire/ --Â BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the second quarter of 2015 and provided a business update.
Second Quarter 2015 Financial SummaryResults are in New Israel Shekels (NIS) and a convenience translation to US$ is provided, using the exchange rate of 3.769 as at June 30, 2015
Total operating expenses were NIS 3.21m ($852,000) compared with NIS 2.18m in the... More